Characterising the prothrombotic changes associated with transcatheter aortic valve implantation: the key to promoting the rational use of anti-thrombotic prophylaxis and minimizing devastating thromboembolic and bleeding complications

St. Andrew's War Memorial Hospital0 个研究点目标入组 40 人开始时间: 2019年1月21日最近更新: 2020年4月27日

适应症

试验速览

暂无简介。

•1) Informed consent for participation;
•2) Either: i) severe aortic stenosis (aortic valve area <0.8cm2, mean aortic valve gradient >40mmHg or peak jet velocity >4m/s); AND planned management with either a TF-TAVI or isolated AVR; OR, ii) Non-ST elevation myocardial infarction (new ischaemic ECG criteria, troponin > upper limit of normal, clinical symptoms); AND planned management with elective PCI; 3) Stable haemoglobin > 100g/l; 4) Non-emergency procedure; 5) Preserved ejection fraction (>50%).

•1) Lack of capacity to consent for him or herself; 2) Medications known to: i) interact with coagulation assays; or ii) have a known or suspected prothrombotic or coagulopathic action that cannot be corrected for by the analysers used for point of care coagulation testing; 3) Known or suspected bleeding or clotting disorders; 4) Severe liver, renal, respiratory or psychiatric disease (including substance abuse); 5) Enrolled in another study with a non-standard treatment intervention.

发起方

St. Andrew's War Memorial Hospital